{"title":"比较巴洛沙韦和奥司他韦对门诊乙型流感患者的疗效","authors":"Takahiro Takazono, Genta Ito, Naoki Hosogaya, Naoki Iwanaga, Takuji Komeda, Masayuki Kobayashi, Yoshitake Kitanishi, Eriko Ogura, Hiroshi Mukae","doi":"10.1111/irv.70002","DOIUrl":null,"url":null,"abstract":"<p>This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (<i>n</i> = 4822) for preventing severe events compared with oseltamivir (<i>n</i> = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use.</p><p><b>Trial Registration:</b> UMIN Clinical Trials Registry Study ID: UMIN000051382</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70002","citationCount":"0","resultStr":"{\"title\":\"Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B\",\"authors\":\"Takahiro Takazono, Genta Ito, Naoki Hosogaya, Naoki Iwanaga, Takuji Komeda, Masayuki Kobayashi, Yoshitake Kitanishi, Eriko Ogura, Hiroshi Mukae\",\"doi\":\"10.1111/irv.70002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (<i>n</i> = 4822) for preventing severe events compared with oseltamivir (<i>n</i> = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use.</p><p><b>Trial Registration:</b> UMIN Clinical Trials Registry Study ID: UMIN000051382</p>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.70002\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use.
Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382
期刊介绍：
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
